Care Access To Begin Enrolling Warwick Residents in Clinical Trial for Potential Heart Attack and Stroke Prevention Drug

New community-based research study will evaluate a potential treatment aimed at preventing major adverse cardiovascular events in high-risk adults

BOSTON--(BUSINESS WIRE)--Care Access, a global research company, is enrolling participants at its Warwick, R.I., location to study the effect of an investigational treatment focused on preventing heart attack and stroke in adults with high risk, but no prior history, of major adverse cardiovascular events.

Major atherosclerotic cardiovascular disease (ASCVD) events, such as heart attack and ischemic stroke, are among the leading causes of death in the United States and worldwide. The VICTORION-1 PREVENT phase 3 study by Novartis (randomized, double-blind, placebo-controlled), may offer a way to help prevent life-threatening medical emergencies caused by the buildup of plaque in the arteries.

“The impact of heart attack and stroke can impede members of our Warwick community from living longer, healthier lives,” said Dr. Sudhir Bansal, Principal Investigator for Care Access - Warwick. “This research study will enroll patients who are at increased risk, but have no prior history, of major ASCVD events. This is an exciting opportunity for our community to participate in a far-reaching study here in Warwick, rather than traveling to the city.”

The clinical trial will enroll adults 40 to 79 years of age who are at high risk for a first major ASCVD event, based on evidence of plaque in the coronary arteries and other factors that physicians can check for. If you or someone you know is interested or wants to participate in this study, visit managemyheartdisease.com, or contact Care Access at [phone] to learn more.

Care Access opened its Warwick location in collaboration with Dr. Bansal and other local healthcare providers. The convenient setting provides residents of Warwick and surrounding communities the option to participate in clinical trials close to home.

About Care Access

Care Access is a global research company helping to accelerate the arrival of new medicines. With a global network of over 150 research sites, Care Access supports research studies conducted by 14 of the top 20 biopharmaceutical companies. In addition to its proven track record of globally top-enrolling sites, Care Access partners with new-to-research communities and establishes high-quality research site infrastructure locally to expand access to clinical trials and increase representation. For research sponsors, Care Access offers three core services: (1) global network of research sites, (2) community screenings to expand a study’s reach, and (3) staffing, on-demand physical space expansion, and training services to support all research sites on a study.

To learn more about active studies at Care Access, or how Care Access helps sponsors achieve enrollment and representation goals, visit www.careaccess.com.